electroCore Q2 2024 Earnings Report $5.87 -0.75 (-11.33%) As of 04:00 PM Eastern Earnings HistoryForecast electroCore EPS ResultsActual EPS-$0.38Consensus EPS -$0.39Beat/MissBeat by +$0.01One Year Ago EPS-$1.03electroCore Revenue ResultsActual Revenue$6.14 millionExpected Revenue$5.85 millionBeat/MissBeat by +$290.00 thousandYoY Revenue GrowthN/AelectroCore Announcement DetailsQuarterQ2 2024Date8/7/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseECOR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads electroCore Earnings HeadlineselectroCore Named One of The Americas’ Fastest Growing Companies by the Financial TimesApril 3 at 8:08 PM | markets.businessinsider.comelectroCore Named One of The Americas' Fastest Growing Companies by the Financial TimesApril 3 at 8:00 AM | globenewswire.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 3, 2025 | Paradigm Press (Ad)electroCore to Participate at the Needham Virtual Healthcare ConferenceApril 1 at 8:00 AM | globenewswire.comelectroCore Extends VA Contract for Five YearsMarch 31 at 8:00 AM | globenewswire.comelectroCore price target lowered to $26 from $28 at LadenburgMarch 13, 2025 | markets.businessinsider.comSee More electroCore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like electroCore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on electroCore and other key companies, straight to your email. Email Address About electroCoreelectroCore (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.View electroCore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
